New Drug Targets Treatment-Resistant Prostate Cancers and Prolongs Trial Participants Lives technologynetworks.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from technologynetworks.com Daily Mail and Mail on Sunday newspapers.
E-Mail
A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today.
Despite progress in medicine in recent years, metastatic castration-resistant prostate cancer remains untreatable and fatal. The new treatment, known as Lu-PSMA-617, takes a new approach, targeting a molecule called PSMA, which is known to be increased on the surfaces of the tumour cells, destroying them and their surrounding microenvironment.
Thousands of men could benefit from a new combination of prostate cancer drugs which cut deaths and shrink tumours.
Patients given two different pills were three times more likely to experience complete remission than those given only one, a trial found.
They were also 23 per cent less likely to die or see their tumour grow or spread.
Doctors at the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust described their findings as promising .
Thousands of men could benefit from a new combination of prostate cancer drugs which cut deaths and shrink tumours (stock image)
And they believe it could improve treatment for more than 10,000 men a year who have advanced prostate cancer with a faulty PTEN gene.
Don t show me this message again✕
The international phase three trial involved 200 sites in 26 countries (PA)
Patients with particularly aggressive prostate cancers can be treated more effectively by a combination of existing targeted medicine and an experimental new drug, new research suggests.
Researchers looked at the efficacy of the targeted hormone drug abiraterone together with a new drug called ipatasertib in patients with advanced prostate cancer who had received no prior treatment.
Abiraterone is a standard medicine taken by many people with advanced prostate cancer. The study, published in The Lancet, found using both medications extended the time before the cancer progressed and spread further.
New drug combination attacks prostate cancer on two fronts – study (David Davies/PA)
Men with particularly aggressive prostate cancers can be treated more effectively by combining an existing targeted medicine with an experimental drug, new research suggests.
Using both medications extended the time before prostate cancers progressed and spread further in men whose tumours lacked a gene known as PTEN.
This is one of the most commonly deleted tumour suppressor genes – which often function to restrain inappropriate cell growth and division – in cancer.
Researchers assessed the efficacy of the targeted hormone drug abiraterone – standard medicine for many men with advanced prostate cancer – together with a new drug called ipatasertib in men with advanced prostate cancer who had received no prior treatment.